- Home
- ACRS vs DSY Comparison
ACRS vs DSY Comparison
Compare ACRS & DSY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRS
- DSY
- Stock Information
- Founded
- ACRS 2012
- DSY 2020
- Country
- ACRS United States
- DSY China
- Employees
- ACRS N/A
- DSY N/A
- Industry
- ACRS Biotechnology: Pharmaceutical Preparations
- DSY
- Sector
- ACRS Health Care
- DSY
- Exchange
- ACRS Nasdaq
- DSY Nasdaq
- Market Cap
- ACRS 132.0M
- DSY 130.7M
- IPO Year
- ACRS 2015
- DSY N/A
- Fundamental
- Price
- ACRS $2.60
- DSY $3.05
- Analyst Decision
- ACRS Strong Buy
- DSY
- Analyst Count
- ACRS 5
- DSY 0
- Target Price
- ACRS $11.00
- DSY N/A
- AVG Volume (30 Days)
- ACRS 956.3K
- DSY 51.6K
- Earning Date
- ACRS 02-25-2025
- DSY 02-10-2025
- Dividend Yield
- ACRS N/A
- DSY N/A
- EPS Growth
- ACRS N/A
- DSY 120.37
- EPS
- ACRS N/A
- DSY 0.01
- Revenue
- ACRS $27,079,000.00
- DSY $7,323,356.00
- Revenue This Year
- ACRS N/A
- DSY N/A
- Revenue Next Year
- ACRS N/A
- DSY N/A
- P/E Ratio
- ACRS N/A
- DSY $279.76
- Revenue Growth
- ACRS 26.35
- DSY 16.37
- 52 Week Low
- ACRS $0.95
- DSY $0.75
- 52 Week High
- ACRS $5.17
- DSY $13.47
- Technical
- Relative Strength Index (RSI)
- ACRS 44.33
- DSY 43.40
- Support Level
- ACRS $2.31
- DSY $2.65
- Resistance Level
- ACRS $2.64
- DSY $3.64
- Average True Range (ATR)
- ACRS 0.16
- DSY 0.43
- MACD
- ACRS 0.02
- DSY -0.04
- Stochastic Oscillator
- ACRS 58.76
- DSY 14.80
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.
About DSY Big Tree Cloud Holdings Limited Ordinary Shares
Big Tree Cloud Holdings Ltd is a consumer-oriented, mission-driven, and technology-empowered company engaged in the development, production, and sales of personal care products and other consumer goods. In particular, it is focused on the development and production of feminine pads and other feminine hygiene products. Through its platform, the company focuses on high-quality product development, deep customer engagement, and efficient sales and marketing.